Resectability, conversion and resections rates, and outcomes in RAS&BRAF wildtype (wt), RAS mutant (mt) and BRAFmt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study.

P. Osterlund,Emerik Osterlund,Aki Uutela,P. Halonen,Raija Kallio,Annika Ålgars,T. Salminen,Annamarja Lamminmäki,L.M. Soveri,Raija Ristamäki,Kaisa I. Lehtomaki,Hanna Stedt,Eetu Heervä,Arno Nordin,Ali Ovissi,Jari Sundström,Lasse Nieminen,Markus Mäkinen,Ari Ristimäki,Helena Isoniemi

Resectability, conversion and resections rates, and outcomes in RAS&BRAF wildtype (wt), RAS mutant (mt) and BRAFmt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study.

2021

3532Background: Outcomes of metastasectomy varies with RAS and BRAF-status, but the effect on resectability, conversion and resection rates has not been extensively studied. Methods: The prospectiv...

Keywords:

Mutant
Internal medicine
Metastasectomy
Medicine
Colorectal cancer
Oncology
Resection
Wild type

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations